COX-2 selective NSAIDs





Introduction

COX-2 selective NSAIDs were developed to reduce the incidence of side-effects seen with traditional NSAIDs, in particular, peptic ulceration. Examples include celecoxib and etoricoxib. Coxibs are not widely used due to ongoing concerns about cardiovascular safety. This led to the withdrawal of rofecoxib ('Vioxx') in 2004.